Coherus Refinances Debt with $55M Term Loan, Extends Maturity to 2031
CHRS is trading near its 52-week low of $1.02 (14% above the low).
Summary
Coherus Oncology refinanced its senior debt with a $55M term loan from Innovatus, lowering its interest rate and extending maturity to 2031.
Key Events · Financing and Capital Events · CHRS
-
New $55M Term Loan
Coherus entered into a $55 million senior secured term loan with Innovatus Life Sciences Lending Fund I, LP on August 12, 2026, and drew the full amount on August 14, 2026.
-
Debt Refinancing
Proceeds were used to repay the prior loan agreement, which had an interest rate of 8.0% plus 3-month SOFR and was scheduled to mature in May 2029. The new loan has a floating rate of 4.15% plus the greater of Prime Rate or 6.75%.
-
Maturity Extension
The new loan matures in August 2031, extending the debt maturity beyond the anticipated launch periods for pipeline product candidates.
-
Optional Additional Tranches
The company has the option to draw additional tranches of $25 million and $20 million under certain conditions.
Analysis · CHRS · Life Sciences
Coherus replaced its existing senior secured term loan with a new $55 million facility from Innovatus Life Sciences Lending Fund. The new loan carries a lower interest rate and extends maturity from May 2029 to August 2031, pushing repayment beyond the anticipated launch of pipeline products. The company drew the full amount on August 14, 2026, using part of the proceeds to repay the prior loan and the remainder for working capital. This refinancing improves near-term liquidity and reduces interest expense, but adds prepayment penalties and a final fee that could be costly if the company repays early.
At the time of this filing, CHRS was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.7M. The 52-week trading range was $1.02 to $2.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.